Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vixotrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 0.98 |
| ▸ | SCN4A | P35499 | 1/20 | 0.98 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.98 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.98 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.98 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.98 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vixotrigine SCHEMBL840484 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL312349 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL841096 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL20562288 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL29388010 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL840179 | 1.00 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL2831660 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL862301 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL311438 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB | |
| Vixotrigine SCHEMBL311437 | 0.99 | KCNH2 (1.00) | KCNH2SCN3ACYP1A2CYP2B6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098150-A1 | Novel Crystalline Forms | BIOGEN MA INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3634400-A1 | NOVEL CRYSTALLINE FORMS | Biogen MA Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3634400-A1 | NOVEL CRYSTALLINE FORMS | Biogen MA Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110913852-A | Novel crystalline forms | 生物基因麻省公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110913852-A | Novel crystalline forms | 生物基因麻省公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20200062705-A1 | NOVEL CRYSTALLINE FORMS | BIOGEN INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062705-A1 | NOVEL CRYSTALLINE FORMS | BIOGEN INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018213686-A1 | NOVEL CRYSTALLINE FORMS | BIOGEN INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2018213686-A1 | NOVEL CRYSTALLINE FORMS | BIOGEN INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-2117535-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008090116-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098150-A1 | Novel Crystalline Forms | SCN5A, HCN4, SCN4A | SCN9A 11/4885KCNH2 20/4885SCN3A 7/4885 |
| US-20200062705-A1 | NOVEL CRYSTALLINE FORMS | SCN5A, KCNQ5, HCN4 | SCN9A 11/4885KCNH2 23/4885SCN3A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.